XI'AN, China, Aug. 25 /Xinhua-PRNewswire/ -- Worldwide Biotech & Pharmaceutical Company (OTC Bulletin Board: WWBP) (''WWBP'') has obtained the China Patent Golden Medal for ''the Intact Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by Cell Culture.''
The project ''The Intact Hepatitis C Virus (HCV) and Method for Culturing HCV in vitro by Cell Culture'' was awarded the Chinese Patent by China Patent Bureau on October 23rd, 2002. The patent was then awarded the prestigious China Patent Golden Medal (Chinese Patent No. 01124001.6) in the 8th China Patent Assessment organized by both General World Intellectual Property Organization (WIPO) and the China Patent Office. Importantly, this patent was recognized by the World Intellectual Property Organization (WIPO), issued as an outstanding Chinese Patented Invention, and was the highest award issued for achievements in the biomedical sciences industry over the past 10 years in China.
''We are highly encouraged with our patent which is recognized by the WIPO and it is such a great achievement for the whole company. It's a great milestone,'' said WenXia Guo, CEO and President of WWBP, ''the success of this patented invention leads our company to a worldwide market, we will continue our development and research of new inventions and bring health to every customer.''
About World Intellectual Property Organization (WIPO)
The World Intellectual Property Organization (WIPO) is an international organization dedicated to promoting the use and protection of works of the human spirit. These works -- intellectual property -- are expanding the bounds of science and technology and enriching the world of the arts. Through its work, WIPO plays an important role in enhancing the quality and enjoyment of life, as well as creating real wealth for nations. With headquarters in Geneva, Switzerland, WIPO is one of the 16 specialized agencies of the United Nations system of organizations. It administers 23 international treaties dealing with different aspects of intellectual property protection.
About Worldwide Biotech & Pharmaceutical Company
Worldwide Biotech & Pharmaceutical Co. (''WWBP'') is a hi-tech biotech company with top-ranking pharmaceutical R&D abilities, Good Manufacturing Practices (GMP) licensed manufacturing facilities and a well-established marketing network in China and Southeast Asia. The product range of WWBP covers Hepatitis C Virus (HCV) products, diagnostic medicines and Over-The-Counter (OTC) drugs. WWBP currently possesses 35,940 square meters of land and 5,359 square meters of GMP standard facilities. With strong pharmaceutical R&D abilities especially in the HCV field, WWBP has been known as the first biotech company in the world to hold the technology of culturing intact HCV in vitro by cell culture. WWBP has achieved a GMP production scale level of 10,000 ml for concentrated HCV material and 10 grams HCV antigen per month, which is expected to bring WWBP considerable gross sale revenue each year and greatly strengthen the company's R&D on anti-HCV drug screen and HCV human vaccine. WWBP had successfully reached two Memoriam of Understanding of Merger Agreements with pharmaceutical companies in China, all of which have scalable production and well-established sales networks, and the acquiring is expected to be finished before the end of September 2005. The acquisitions will strengthen WWBP's R&D abilities and production scale, as well as extend its marketing network throughout China and Southeast Asia. WWBP has been working closely with pharmaceutical research institutes, and has established connections with both central & local governments. Safe Harbor Information in this news release may contain statements about future expectations, plans, prospects or performance of Worldwide Biotech & Pharmaceutical Co. that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Worldwide Biotech & Pharmaceutical Co. cautions you that any forward-looking information provided by or on behalf of Worldwide Biotech & Pharmaceutical Co. is not a guarantee of future performance. None of the information on this website constitutes an offer to sell securities or investment advice of any kind, and visitors should not base their investment decisions on information contained in this website. Worldwide Biotech & Pharmaceutical Co.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Worldwide Biotech & Pharmaceutical Co.'s control. In addition to those discussed in Worldwide Biotech & Pharmaceutical Co.'s press releases, public filings, and statements by Worldwide Biotech & Pharmaceutical Co.'s management, including, but not limited to, Worldwide Biotech & Pharmaceutical Co.'s estimate of the sufficiency of its existing capital resources, Worldwide Biotech & Pharmaceutical Co.'s ability to raise additional capital to fund future operations, Worldwide Biotech & Pharmaceutical Co.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Worldwide Biotech & Pharmaceutical Co.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Worldwide Biotech & Pharmaceutical Co. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
